Trial Profile
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Oct 2017
Price :
$35
*
At a glance
- Drugs Rivastigmine (Primary) ; Rivastigmine
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Acronyms IDEAL
- Sponsors Novartis
- 01 Oct 2016 Results of population pharmacokinetic analysis, assessing effects of renal impairment on steady-state plasma concentrations of rivastigmine and its metabolite NAP226-90 after rivastigmine patch and capsule treatment in patients with Alzheimer's disease, published in Drugs and Aging Journal.
- 28 Sep 2016 Results of population pharmacokinetic analysis, assessing effects of renal impairment on steady-state plasma concentrations of rivastigmine and its metabolite NAP226-90 after rivastigmine patch and capsule treatment in patients with Alzheimer's disease, published in Drugs and Aging Journal.
- 15 Oct 2005 New trial record.